How a 'Regulatory Dead Zone' May Be Holding Up Copycat Insulin
January 14, 2019
Andrew Dunn
BioPharma Dive
Axinn partner Chad Landmon was quoted in the BioPharma Dive article, "How a 'Regulatory Dead Zone' May Be Holding Up Copycat Insulin."
Click here to access the article.